LILLY's CESAMET (NABILONE) LAUNCH AWAITS DEA SCHEDULING of the synthetic cannabinoid, Lilly said. Cesamet, which is chemically related to THC, was approved by FDA on Dec. 27 "for use in the treatment of nausea and vomiting associated with cancer chemotherapy." Lilly said the drug "is indicated for those patients who have failed to respond adequately to conventional anti-emetic treatment." A course of therapy "runs one to five days concomitantly with chemotherapy," Lilly said. Once scheduled by the Drug Enforcement Agency and introduced, Cesamet will compete with Unimed's Marinol (dronabinol or THC) which is approved for the same indication. Marinol, approved June 6, still has not come to market because of delays in DEA scheduling. Unimed President Paul Bollenbacher recently denied rumors that the DEA decided not to reclassify the marijuana-derived product from Schedule I to II. He explained that despite a six month delay, DEA "reassured" the firm of the agency's intent to reschedule the product to the less restrictive Shedule II ("The Pink Sheet" Dec. 16, "In Brief"). In April 1983, FDA's Drug Abuse Advisory Cmte. recommended that Cesamet be placed in Schedule III under the Controlled Substances Act. Despite FDA's position at that time that nabilone and THC are "essentially identical in abuse potential," the cmte. recommended Schedule III for Cesamet after having recommended Schedule II for THC. Cesamet is currently marketed as an anti-emetic in Canada and the U.K. Those approvals were granted in 1982 and 1983, respectively. Lilly noted that it will not determine the price of Cesamet until the product clears DEA.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
